Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omeprazole

FDA-approved product (capsule, delayed rel pellets, oral), marketed as Omeprazole, Prilosec, Omeprazole Magnesium and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Omeprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Infection
  • Peptic ulcer
  • Peptic ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Proton pump inhibitors
FDA pharmacologic class
Proton Pump Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omeprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omeprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CYP2C19 Genotype Predictor of Gastric Acid Suppression

    NCT01824199 · start 2013-03

    Registered record
    Registry ID
    NCT01824199
    Conditions
    Esophagitis
    Interventions
    Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2013-03
    Completion
    2016-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophagitis
    InterventionOmeprazole
    PhaseEarly phase 1
    Registry statusWithdrawn

  • A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

    NCT01265550 · start 2012-08-13

    Registered record
    Registry ID
    NCT01265550
    Conditions
    GERD
    Interventions
    Nissen fundoplication; baclofen; Desipramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08-13
    Completion
    2016-12-30
    Enrolment
    366

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD
    InterventionNissen fundoplication; baclofen; Desipramine
    PhasePhase 3
    Registry statusCompleted

  • Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR

    NCT01755221 · start 2012-08

    Registered record
    Registry ID
    NCT01755221
    Conditions
    Laryngopharyngeal Reflux (LPR); Extraesophageal Reflux; Reflux Laryngitis; Posterior Laryngitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-08
    Completion
    2016-08
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaryngopharyngeal Reflux (LPR); Extraesophageal Reflux; Reflux Laryngitis; Posterior Laryngitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)

    NCT01587885 · start 2012-01

    Registered record
    Registry ID
    NCT01587885
    Conditions
    Heartburn
    Interventions
    Omeprazole 20 mg + Sodium Bicarbonate 1100 mg; Omeprazole 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-05
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeartburn
    InterventionOmeprazole 20 mg + Sodium Bicarbonate 1100 mg; Omeprazole 20 mg
    PhasePhase 4
    Registry statusCompleted

  • Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease

    NCT01493089 · start 2011-04

    Registered record
    Registry ID
    NCT01493089
    Conditions
    Gastroesophageal Reflux
    Interventions
    Zegerid; Losec
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-10
    Enrolment
    239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux
    InterventionZegerid; Losec
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

    NCT01147588 · start 2010-05

    Registered record
    Registry ID
    NCT01147588
    Conditions
    Healthy
    Interventions
    lansoprazole; omeprazole; esomeprazole; clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-05
    Completion
    2011-05
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionlansoprazole; omeprazole; esomeprazole; clopidogrel
    PhasePhase 1
    Registry statusCompleted

  • Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

    NCT01135472 · start 2010-03

    Registered record
    Registry ID
    NCT01135472
    Conditions
    Healthy
    Interventions
    Esomeprazole Magnesium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEsomeprazole Magnesium
    PhasePhase 1
    Registry statusCompleted

  • Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin

    NCT01062516 · start 2010-01

    Registered record
    Registry ID
    NCT01062516
    Conditions
    Acute Coronary Syndrome; Acute Myocardial Infarction
    Interventions
    esomeprazole 20 mg daily; famotidine 40 mg daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Acute Myocardial Infarction
    Interventionesomeprazole 20 mg daily; famotidine 40 mg daily
    PhasePhase 4
    Registry statusCompleted

  • Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole

    NCT00971581 · start 2009-08

    Registered record
    Registry ID
    NCT00971581
    Conditions
    Pain
    Interventions
    FDC KETOPROFEN+OMEPRAZOLE
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-05
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionFDC KETOPROFEN+OMEPRAZOLE
    PhasePhase 3
    Registry statusCompleted

  • Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

    NCT00818870 · start 2008-12

    Registered record
    Registry ID
    NCT00818870
    Conditions
    Gastroesophageal Reflux
    Interventions
    Omeprazole; Vecam; Vecam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux
    InterventionOmeprazole; Vecam; Vecam
    PhasePhase 1
    Registry statusCompleted

  • Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

    NCT01983774 · start 2008-02

    Registered record
    Registry ID
    NCT01983774
    Conditions
    Cystic Fibrosis
    Interventions
    Esomeprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2011-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionEsomeprazole; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice

    NCT00363701 · start 2006-08

    Registered record
    Registry ID
    NCT00363701
    Conditions
    Dyspepsia; Gastroesophageal Refluxdisease; Ulcer
    Interventions
    esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2006-08
    Completion
    2008-02
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspepsia; Gastroesophageal Refluxdisease; Ulcer
    Interventionesomeprazole
    PhasePhase 4
    Registry statusUnknown

  • Nexium Study To Suppress Nausea During Chemotherapy

    NCT00206440 · start 2005-08

    Registered record
    Registry ID
    NCT00206440
    Conditions
    Nausea
    Interventions
    esomeprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2005-08
    Completion
    2012-02
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea
    Interventionesomeprazole; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

    NCT00079833 · start 2003-11

    Registered record
    Registry ID
    NCT00079833
    Conditions
    Zollinger-Ellison Syndrome
    Interventions
    Esomeprazole magnesium (Nexium)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    2005-07
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionZollinger-Ellison Syndrome
    InterventionEsomeprazole magnesium (Nexium)
    PhasePhase 3
    Registry statusCompleted

  • Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD

    NCT02407119 · start 2003-06

    Registered record
    Registry ID
    NCT02407119
    Conditions
    Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection
    Interventions
    7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin; Placebo, Omeprazole or Rabeprazole, Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2003-06
    Completion
    2030-06
    Enrolment
    470

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection
    Intervention7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin; Placebo, Omeprazole or Rabeprazole, Clarithromycin
    PhasePhase 3
    Registry statusActive not recruiting